Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma
Authors:
- 21 January 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 220 (12) , 1885-1891
Abstract
Background: Chronic immune activation in the blood and central nervous system is a consequence of human immunodeficiency virus (HIV) infection that contributes to disease morbidity and can occur despite virally suppressive antiretroviral therapy (ART). The trajectory of HIV-related inflammation may vary with the timing of ART initiation. We examined immune activation markers in cerebrospinal fluid (CSF) and blood specimens collected over 96 weeks from participants who initiated ART during acute HIV infection (AHI). Methods: RV254/SEARCH010 study participants with AHI underwent CSF (n = 89) and plasma (n = 146) sampling before initiating ART and at weeks 24 and 96 of treatment. A majority participants (64.4%) received a standard ART regimen (hereafter, “standard ART”), with some (34.7%) also receiving maraviroc and raltegravir for the first 24 weeks (hereafter, “ART plus”). We compared neopterin, CXCL10, CCL2, and interleukin 6 (IL-6) levels in the AHI group to those in 18 healthy, uninfected controls. Results: Following 24 and 96 weeks of treatment, levels of all CSF markers normalized while levels of several plasma markers remained elevated in the AHI group (P < .001). Participants receiving the ART-plus regimen had lower median plasma CCL2 levels at week 24 and lower plasma neopterin levels at week 96. Conclusions: ART initiation during AHI differentially impacts the brain compartment, with markers of inflammation returning to normal levels in the CSF, where they were sustained at week 96, but not in plasma.Keywords
Funding Information
- National Institute of Mental Health
- National Institutes of Health (K23MH114724, R01MH095613, R01NS061696, R21MH086341, R01NS084911, K24MH098759)
- Henry M. Jackson Foundation for the Advancement of Military Medicine
This publication has 16 references indexed in Scilit:
- Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatmentAIDS, 2018
- Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infectionJournal of Neuroinflammation, 2018
- Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infectionAIDS, 2017
- Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individualsAIDS, 2016
- Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive ImpairmentPLOS ONE, 2016
- Neuroinflammation in treated HIV-positive individualsNeurology, 2016
- Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV InfectionThe Journal of Infectious Diseases, 2015
- Residual Immune Dysregulation Syndrome in Treated HIV infection2013
- Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral BurdenThe Journal of Infectious Diseases, 2011
- Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008